Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul K Paik

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Cancer Discovery|June 5, 2016
Something Old, Something New, Something Borrowed, Something Fused: Novel EGFR Rearrangements in Lung AdenocarcinomasPaul K Paik
Cancer|April 2, 2025
From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingWiktoria Bogdanska, Paul K Paik
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 26, 2009
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trialsPaul K Paik, Lee M Krug
Cancer|June 18, 2016
Missing the mark in FGFR1-amplified squamous cell cancer of the lungPaul K Paik, Charles M Rudin
Annals of Translational Medicine|October 24, 2017
Relevance of genetic alterations in squamous and small cell lung cancerJoshua K Sabari, Paul K Paik
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologiesDavid E Gerber, Paul K Paik, Afshin Dowlati
Journal of Thoracic Disease|January 12, 2019
Liquid biopsy guided precision therapy for lung cancersChongrui Xu, Michael Offin, Paul K Paik, et al.
Clinical Lung Cancer|November 18, 2025
Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment OptionsPaul K Paik, Jianjun Zhang, Howard Jack West, et al.
Advances in Therapy|May 11, 2022
Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping MutationsPaul K Paik, Boris M Pfeiffer, Helene Vioix, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
New Treatment Options in Advanced Squamous Cell Lung CancerPaul K Paik, Rathi Narayana Pillai, Christopher S Lathan, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Cancer Discovery|June 5, 2016
Something Old, Something New, Something Borrowed, Something Fused: Novel EGFR Rearrangements in Lung AdenocarcinomasPaul K Paik
Cancer|April 2, 2025
From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingWiktoria Bogdanska, Paul K Paik
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 26, 2009
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trialsPaul K Paik, Lee M Krug
Cancer|June 18, 2016
Missing the mark in FGFR1-amplified squamous cell cancer of the lungPaul K Paik, Charles M Rudin
Annals of Translational Medicine|October 24, 2017
Relevance of genetic alterations in squamous and small cell lung cancerJoshua K Sabari, Paul K Paik
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologiesDavid E Gerber, Paul K Paik, Afshin Dowlati
Journal of Thoracic Disease|January 12, 2019
Liquid biopsy guided precision therapy for lung cancersChongrui Xu, Michael Offin, Paul K Paik, et al.
Clinical Lung Cancer|November 18, 2025
Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment OptionsPaul K Paik, Jianjun Zhang, Howard Jack West, et al.
Advances in Therapy|May 11, 2022
Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping MutationsPaul K Paik, Boris M Pfeiffer, Helene Vioix, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
New Treatment Options in Advanced Squamous Cell Lung CancerPaul K Paik, Rathi Narayana Pillai, Christopher S Lathan, et al.
Pageof 9